EVOLVA HOLDING SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.946 CHF | -6.34% |
|
+0.42% | +31.39% |
| 04-15 | Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting | MT |
| 03-26 | Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation | MT |
| Sales 2022 | 15.54M 16.99M 1.36B | Sales 2023 | 4.16M 4.54M 364M | Capitalization | 4.9M 5.36M 429M |
|---|---|---|---|---|---|
| Net income 2022 | -43M -47.02M -3.77B | Net income 2023 | -101M -110M -8.85B | EV / Sales 2022 | 6.5 x |
| Net Debt 2022 | 9.91M 10.84M 868M | Net cash position 2023 | 5.84M 6.38M 511M | EV / Sales 2023 | -0.23 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.05
x | Employees | 49 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evolva Holding SA
More recommendations
More press releases
More news
| 1 day | -6.34% | ||
| 1 week | +0.42% | ||
| Current month | -6.34% | ||
| 1 month | -7.71% | ||
| 3 months | +39.12% | ||
| 6 months | -70.25% | ||
| Current year | +31.39% |
1 week
0.94
1.01
1 month
0.901.08
Current year
0.621.09
1 year
0.6219.00
3 years
0.6249.25
5 years
0.6293.50
10 years
0.62465.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 07/02/22 | |
Gerhard Lobmaier
COO | Chief Operating Officer | 55 | 31/12/20 |
Astrid Schäfer
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/12/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 14/04/20 | |
Beat In-Albon
BRD | Director/Board Member | 72 | 14/04/20 |
Andreas Pfluger
BRD | Director/Board Member | 64 | 31/03/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.946 | -6.34% | 3,184 |
| 25/04/24 | 1.01 | +6.99% | 11,574 |
| 24/04/24 | 0.944 | -6.53% | 658 |
| 23/04/24 | 1.01 | +7.22% | 7,450 |
| 22/04/24 | 0.942 | 0.00% | 118 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotes
Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and increase the yield and efficiency of the production of various ingredients.
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.39% | 7.46M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EVE Stock
